Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

4/15/25 12:40:56 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AZN

Date	Price Target	Rating	Analyst
4/15/2025	$75.00	Outperform	Exane BNP Paribas
2/13/2025		Neutral → Buy	UBS
2/12/2025		Overweight	Morgan Stanley
11/20/2024		Sell → Neutral	UBS
11/6/2024		Sell → Hold	Deutsche Bank
9/13/2024		Hold → Sell	Deutsche Bank
5/30/2024	$97.00	Buy	Goldman
4/16/2024		Sell → Hold	Deutsche Bank